NLS Pharmaceutics AG (NASDAQ:NLSPW) — Market Cap & Net Worth
Market Cap & Net Worth: NLS Pharmaceutics AG (NLSPW)
NLS Pharmaceutics AG (NASDAQ:NLSPW) has a market capitalization of $173.49 ($173.49) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #31475 globally and #6055 in its home market, demonstrating a 37.69% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying NLS Pharmaceutics AG's stock price $0.02 by its total outstanding shares 9692 (9.69K). Analyse how efficiently does NLS Pharmaceutics AG generate cash to see how efficiently the company converts income to cash.
NLS Pharmaceutics AG Market Cap History: 2021 to 2025
NLS Pharmaceutics AG's market capitalization history from 2021 to 2025. Data shows change from $4.85K to $173.49 (-54.14% CAGR).
NLS Pharmaceutics AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how NLS Pharmaceutics AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of NLSPW by Market Capitalization
Companies near NLS Pharmaceutics AG in the global market cap rankings as of May 4, 2026.
Key companies related to NLS Pharmaceutics AG by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
NLS Pharmaceutics AG Historical Marketcap From 2021 to 2025
Between 2021 and today, NLS Pharmaceutics AG's market cap moved from $4.85K to $ 173.49, with a yearly change of -54.14%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $173.49 | +37.69% |
| 2024 | $126.00 | -76.79% |
| 2023 | $542.75 | -80.69% |
| 2022 | $2.81K | -42.00% |
| 2021 | $4.85K | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of NLS Pharmaceutics AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $173.49 USD |
| MoneyControl | $173.49 USD |
| MarketWatch | $173.49 USD |
| marketcap.company | $173.49 USD |
| Reuters | $173.49 USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About NLS Pharmaceutics AG
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity … Read more